Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs

Abstract

CTI 52010 was well tolerated when administered intravenously to normal dogs. A starting dosage for a Phase I/II trial in tumor-bearing dogs is 80 mg/m(2).